22nd Century Group, Inc. (XXII): Price and Financial Metrics


22nd Century Group, Inc. (XXII): $0.76

-0.01 (-0.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XXII to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XXII POWR Grades

  • XXII scores best on the Momentum dimension, with a Momentum rank ahead of 43.83% of US stocks.
  • XXII's strongest trending metric is Momentum; it's been moving up over the last 177 days.
  • XXII's current lowest rank is in the Sentiment metric (where it is better than 3.19% of US stocks).

XXII Stock Summary

  • XXII's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 12.61% of US stocks.
  • With a year-over-year growth in debt of 188.14%, 22ND CENTURY GROUP INC's debt growth rate surpasses 92.86% of about US stocks.
  • As for revenue growth, note that XXII's revenue has grown 100.7% over the past 12 months; that beats the revenue growth of 93.01% of US companies in our set.
  • Stocks that are quantitatively similar to XXII, based on their financial statements, market capitalization, and price volatility, are FTFT, XERS, FNA, OGI, and LIQT.
  • Visit XXII's SEC page to see the company's official filings. To visit the company's web site, go to www.xxiicentury.com.

XXII Valuation Summary

  • In comparison to the median Healthcare stock, XXII's EV/EBIT ratio is 142.42% lower, now standing at -2.8.
  • Over the past 148 months, XXII's EV/EBIT ratio has gone up 208.3.

Below are key valuation metrics over time for XXII.

Stock Date P/S P/B P/E EV/EBIT
XXII 2023-03-24 2.6 1.7 -2.7 -2.8
XXII 2023-03-23 2.5 1.6 -2.6 -2.7
XXII 2023-03-22 2.8 1.8 -2.9 -3.0
XXII 2023-03-21 3.0 2.0 -3.1 -3.2
XXII 2023-03-20 2.8 1.8 -2.9 -3.0
XXII 2023-03-17 3.0 2.0 -3.1 -3.2

XXII Growth Metrics

    Its year over year price growth rate is now at -57.21%.
  • The 3 year net income to common stockholders growth rate now stands at -219.42%.
  • Its 3 year net cashflow from operations growth rate is now at -38.56%.
Over the past 33 months, XXII's revenue has gone up $25,032,470.

The table below shows XXII's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 50.865 -37.28 -47.483
2022-06-30 39.293 -30.321 -43.821
2022-03-31 33.187 -26.856 -36.497
2021-12-31 30.948 -22.839 -32.609
2021-09-30 30.296 -21.204 -25.048
2021-06-30 29.795 -16.418 -19.829

XXII's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XXII has a Quality Grade of F, ranking ahead of 0.97% of graded US stocks.
  • XXII's asset turnover comes in at 0.448 -- ranking 5th of 5 Tobacco Products stocks.
  • MO, TPB, and PM are the stocks whose asset turnover ratios are most correlated with XXII.

The table below shows XXII's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.448 0.073 -0.387
2021-03-31 0.485 0.065 -0.480
2020-12-31 0.479 0.051 -0.435
2020-09-30 0.446 0.038 -0.388
2020-06-30 0.425 0.025 -0.494
2020-03-31 0.400 0.015 -0.537

XXII Price Target

For more insight on analysts targets of XXII, see our XXII price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.33 Average Broker Recommendation 1.5 (Moderate Buy)

XXII Stock Price Chart Interactive Chart >

Price chart for XXII

XXII Price/Volume Stats

Current price $0.76 52-week high $2.70
Prev. close $0.76 52-week low $0.71
Day low $0.74 Volume 991,000
Day high $0.77 Avg. volume 1,112,075
50-day MA $0.96 Dividend yield N/A
200-day MA $1.27 Market Cap 163.14M

22nd Century Group, Inc. (XXII) Company Bio


22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company was founded in 1998 and is based in Clarence, New York.


XXII Latest News Stream


Event/Time News Detail
Loading, please wait...

XXII Latest Social Stream


Loading social stream, please wait...

View Full XXII Social Stream

Latest XXII News From Around the Web

Below are the latest news stories about 22ND CENTURY GROUP INC that investors may wish to consider to help them evaluate XXII as an investment opportunity.

22nd Century Group (Nasdaq: XXII) Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Accelerates VLN® Launch with Key National Distribution AgreementsLaunching VLN® in Texas, California and Florida with New National Scale Distributor and Retail PartnersScaling Hemp/Cannabis Revenue and Gross Margin to Achieve Cash-Positive Operating Results in First Half 2024; Executing New Fully Verticalized Major Retail Category Management Services AgreementsFourth Quarter 2022 Net Revenues $19.2 Million, Up 141% from the Fourth Quarter 2021New $21.1 Million Senior Secured Credit Facility Expa

Yahoo | March 9, 2023

22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives

Supports Accelerated Expansion of VLN Multi-State Retail Channels, GVB Global Ingredients and CDMO BusinessBUFFALO, N.Y., March 03, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the world’s leading biotechnology company dedicated to improving health with reduced nicotine tobacco and advanced plant technologies in both hemp/cannabis and hops, today announced a new $21 million senior secured debenture financing to support increased working capital needs related to the significa

Yahoo | March 3, 2023

22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor Conference

BUFFALO, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that the Company will be participating in one-on-one meetings during the 35th Annual Roth Conference, to be held March 12-14, 2023 in Orange County, California. Investors and attendees that would like to schedule a meeting with 22nd Century’s manag

Yahoo | March 2, 2023

22nd Century Group (Nasdaq: XXII) to Announce Fourth Quarter and Full Year 2022 Results on March 9, 2023

BUFFALO, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, will host a live webcast on Thursday, March 9, 2023, at 10:00 AM ET to discuss its 2022 fourth quarter and full year results, which are to be reported in a press release at 6:00 AM ET the same day. During the webcast, James A. Mish, chief executive officer; John Mi

Yahoo | February 23, 2023

22nd Century Group (XXII) Accelerates Major Growing Program to Enable Implementation of New Zealand’s Reduced-Nicotine Content Tobacco Law

Seeding Program Will Produce Tobacco for Up To 2 Billion Sticks – The Entire Annual Cigarette Consumption of New Zealand – To Make Reduced Nicotine Content Cigarettes Readily Available at National Scale VLN® Poised to Serve as the Foundational Cigarette for Reduced Nicotine Content Public Health Policies Worldwide BUFFALO, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, h

Yahoo | February 22, 2023

Read More 'XXII' Stories Here

XXII Price Returns

1-mo -17.91%
3-mo -7.32%
6-mo -19.39%
1-year -67.80%
3-year 2.83%
5-year -67.66%
YTD -17.44%
2022 -70.21%
2021 40.45%
2020 100.00%
2019 -55.82%
2018 -11.07%

Continue Researching XXII

Here are a few links from around the web to help you further your research on 22nd Century Group Inc's stock as an investment opportunity:

22nd Century Group Inc (XXII) Stock Price | Nasdaq
22nd Century Group Inc (XXII) Stock Quote, History and News - Yahoo Finance
22nd Century Group Inc (XXII) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8024 seconds.